Bio-Techne (TECH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.52
- Estimate
- $0.52
- Surprise
- +0.1%
- Score at report (before → after)
- 5.3 → 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Bio-Techne (TECH) reported diluted EPS of $0.52, in line with the $0.52 estimate. TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Sell at 5.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates TECH Sell at 5.0/10.
1 of the last 4 quarters beat the estimate; this quarter's +0.1% surprise compares with a +1.2% four-quarter average. Next scheduled report: 2026-11-09.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: Protein Sciences segment (72.0%)
- Analyst target reached - limited upside remaining
- Near 52-week high (0.2% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $72.34
- Price target
- $83.32
- Stop
- $72.03
- Upside to target
- +15.2%
The stock trades at 62.5× trailing but 31.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
TECH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $11.36B
- P/E (fwd)
- 31.4
- P/E (ttm)
- 62.5
- 52-week range
- $43.20–$72.62
- Off 52-week high
- 0.4%
- RSI (14)
- 54
- Volume vs avg
- 0.98×
- Score today
- 5.0/10